Trial Profile
A Phase II Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Therapeutic Use
- 07 Apr 2021 Status changed from active, no longer recruiting to completed.
- 04 Aug 2020 According to a Karyopharm Therapeutics media release, results from this trial were published in The Lancet Haematology.
- 06 Apr 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.